Good Life

A few telehealth brands were still reported in 2026 as offering compounded GLP-1s despite the FDA crackdown, but the landscape is changing fast and many providers have shifted to branded drugs or stopped compounded GLP-1 sales altogether.[2][5][7][12] The clearest names mentioned in the search results as still involved are: Hims & Hers — Reuters and Yahoo Finance both describe Hims as continuing to be scrutinized while still connected to compounded GLP-1 offerings, even after moving into branded-drug partnerships.[2][7][12] Ro — Yahoo Finance reports Ro continued to provide compounded GLP-1 versions, including semaglutide, despite recent partnerships with Lilly.[7] Noom — Yahoo Finance also says Noom continued offering compounded GLP-1 versions.[7] MD Exam — a Reddit comment in the results says compounded GLP-1 access was still available through MD Exam, but this is not as authoritative as FDA or Reuters reporting.[11] Good Life — also mentioned only in that Reddit discussion as a possible still-active option.[11] The FDA’s enforcement focus has been on false or misleading marketing around compounded GLP-1s, especially claims that these products are equivalent to approved drugs or that telehealth companies themselves are the manufacturers.[1][6][8] The FDA also issued warning letters to many telehealth firms, including names such as Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, GoodGirlRx, and others listed in the reporting.[3][8][11] If you want, I can turn this into a current “still offering vs. stopped” list by brand and flag which ones appear to have switched to branded Wegovy/Zepbound instead of compounded semaglutide/tirzepatide.

Mentioned in position 5 of 12

No telehealth services are confirmed to still safely offer compounded GLP-1s after the FDA’s March and June 2026 crackdowns; major platforms have either stopped offering them entirely or transitioned exclusively to FDA-approved alternatives like Wegovy, Zepbound, and Saxenda [3]. The FDA has issued over 100 warning letters across three enforcement waves (February, March, and June 2026) to telehealth firms for promoting compounded GLP-1s with false or misleading claims, explicitly stating these products lack proven safety, efficacy, or consistent quality [1][2][5]. High-profile companies that previously offered compounded versions have exited the model: Company Status After Crackdown Hims & Hers Exited compounded semaglutide entirely in March 2026; now an authorized distributor of branded Wegovy and Ozempic [3][10] Ro Stopped compounded GLP-1s; now offers Wegovy and Zepbound [3] Good Life Eliminated compounded offerings; focuses on FDA-approved alternatives [3] Medica Weight Loss, Ready Med, Clover Meds Received June 2026 warning letters; compliance status unclear but likely halted or under review [1] Beluga Health, OpenLoop, MD Integrations Affiliations warned; at least 30% of warned companies linked to these groups, suggesting widespread cessation [6] The post-crackdown landscape is shifting to a manufacturer-centric distribution network, where Novo Nordisk and Eli Lilly offer direct-to-telehealth programs bundling FDA-approved drugs with adherence kits and reimbursement interfaces [2]. If you are seeking weight-loss treatment, the safest and most reliable options are currently: Wegovy (Novo Nordisk) – FDA-approved for chronic weight management [3] Zepbound (Eli Lilly) – FDA-approved for weight loss [3] Saxenda (Novo Nordisk) – FDA-approved, often used with generics [3] For access, consult licensed telehealth platforms that now focus on approved medications, such as Ro and Hims & Hers [3]. Compounded GLP-1s remain legally permissible only in rare cases (e.g., specific allergies or unavailable dosages), but mainstream telehealth platforms have largely eliminated them [3][12].

Mentioned in position 3 of 11

No telehealth services are confirmed to still safely offer compounded GLP-1s after the FDA’s March 2026 and June 2026 crackdowns, as major companies—including Ro, Hims & Hers, Good Life, and others—have either stopped offering them entirely or transitioned to FDA-approved alternatives like Wegovy, Zepbound, and Saxenda. The FDA issued 30 warning letters in March 2026 and 25 additional warning letters in June 2026 to telehealth companies for falsely or misleadingly marketing compounded GLP-1 products, which the agency explicitly states are not FDA-approved and lack proven safety, efficacy, or consistent quality [1][2][3][4]. Most prominent healthcare providers now either prescribe compounded medications only when legally permitted (e.g., for allergies or unavailable dosages) or have eliminated compounded GLP-1 use altogether [2]. If you are seeking weight-loss treatment, the safest and most reliable options are currently: Wegovy (Novo Nordisk) – FDA-approved for chronic weight management [2] Zepbound (Eli Lilly) – FDA-approved for weight loss [2] Saxenda (Novo Nordisk) – FDA-approved, often used with generics [2] For access to these, consult licensed telehealth platforms that now focus on approved medications, such as: Ro (now offers Wegovy and Zepbound) Hims & Hers (shifted to FDA-approved GLP-1s) Amble Health (mentioned in context, but verify current offerings) [5] Always verify a company’s compliance status on the FDA’s Warning Letters page before signing up, as enforcement remains aggressive and ongoing [1][3].

Mentioned in position 3 of 9